Long-Term Data Shows Feasibility of Adjuvant Trials in Prostate Cancer
This video examines long-term findings from a trial that tested ADT alone vs ADT plus chemotherapy as adjuvant therapy for patients with high-risk prostate cancer, including some surprising results and important takeaways.
In this video, L. Michael Glodé, MD, discusses long-term findings from a trial that tested 2 years of androgen-deprivation therapy (ADT) vs 2 years of ADT plus mitoxantrone and prednisone following radical prostatectomy in patients with high-risk prostate cancer. Glodé highlights some of the surprising results and important takeaways.
The trial, which began accrual in 1999, included 961 eligible patients but was stopped early due to a significant increase in cases of acute myeloid leukemia in the experimental arm. The 10-year overall survival rate was similar between the two groups (87% with ADT alone vs 86% with ADT plus chemotherapy).
Results of the study (abstract 2) were presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
